Alzheimer s Disease Costs: What We Know and What We Should Take into Account

Size: px
Start display at page:

Download "Alzheimer s Disease Costs: What We Know and What We Should Take into Account"

Transcription

1 Journal of Alzheimer s Disease 42 (2014) DOI /JAD IOS Press 1311 Alzheimer s Disease Costs: What We Know and What We Should Take into Account Luisa Colucci a,b, Massimiliano Bosco b, Angiola Maria Fasanaro b, Giuseppe Lucio Gaeta c, Giovanna Ricci d and Francesco Amenta a, a Centro Ricerche Cliniche, Telemedicina e Telefarmacia, Università di Camerino, Camerino, Italy b Unità Valutativa Alzheimer e Malattie Involutive Cerebrali, Azienda Ospedaliera Rilievo Nazionale A. Cardarelli, Napoli, Italy c Dipartimento di Scienze Sociali ed Umane, Università di Napoli l Orientale, Napoli, Italy d Scuola di Giurisprudenza, Università di Camerino, Camerino, Italy Handling Associate Editor: Richard Dodel Accepted 8 May 2014 Abstract. Background/Objective: Alzheimer s disease (AD) is a very costly pathology. Total costs of AD result from the sum of direct and indirect costs. Intangible costs represent an additional burden that is difficult to quantify. This paper has reviewed the evaluation of the costs of AD and the methodologies to estimate them, and proposes the use of some tools which may be useful in establishing the financial weight of the disease. Method: A systematic literature search was conducted using the Pubmed and Medline databases as a source of published papers. Results: In AD, direct and indirect costs and their sum (total costs) are very high and tend to increase parallel with the evolution of the pathology. The evolution of AD is characterized by the loss of functional autonomy, the onset of behavioral and sleep disorders, and the development of delusions and hallucinations. This requires more frequent medical examinations and hospitalizations resulting in higher direct costs, which become the relevant weight. None of the papers reviewed investigated intangible cost. Conclusion: The calculation of costs of AD is frequently based on cognitive decline and the degree of dependence of patients. The evaluation of intangible costs (psychological pain of the patient and of the unpaid caregivers and their impaired quality of life) is a missing aspect in all reviewed studies. Due to the complexity of AD, it will be necessary to adopt cost evaluation systems including the different dimensions of the problem and its various aspects. Keywords: Costs of Alzheimer s disease, direct costs, evaluation costs, indirect costs, intangible costs, total costs INTRODUCTION If dementia care were a country, it would be the world s 18th largest economy [1]. This statement of the Alzheimer s Association highlights the magnitude of the economic burden of dementia which is doomed to increase dramatically in the near future. It was been estimated that 35.6 million people live Correspondence to: Francesco Amenta, Centro Ricerche Cliniche, Telemedicina e Telefarmacia, Università di Camerino, Via Madonna delle Carceri 9, Camerino, Italy. Tel.: ; Fax: ; francesco.amenta@unicam.it. with dementia worldwide [2]. They are estimated to be 65.7 million in 2030 and million in 2050 [2], and this disease will probably reach third place in terms of total costs after cancer and cardiovascular disorders [3]. Alzheimer s disease (AD) therefore represents a very relevant challenge both from a medical and an economical perspective. Several studies have tried to evaluate the costs related to the disease with the vast majority dividing them between direct and indirect costs. Direct costs are related to the money spent on the diagnosis, follow up, and treatment of patients. They include the expenses for health services, ISSN /14/$ IOS Press and the authors. All rights reserved

2 1312 L. Colucci et al. / Costs of AD pharmacotherapy, and hospitalization, as well as those of the possible institutionalization. Indirect costs are related to the resources lost because of the disease, such as the loss of productivity in case patients still work. They also include the reduced productivity in those family members who provide unpaid assistance to the ill person. The sum of direct and indirect costs represents the total costs of the disease. However, other costs should be included in the global economic evaluation: they are related to the psychological pain of the patient and of the unpaid caregivers and to their impaired quality of life. These aspects, even if difficult to translate in economic values, are relevant and deserve attention [4]. Their monetary assessment, in fact, not only reflects an important aspect of the disease burden, but may significantly encourage families to postpone or avoid as much as possible the institutionalization of their relatives. Several reviews articles have analyzed the costs of the disease and discussed methods adopted and cost-effectiveness of different drug treatments. These reviews confirm the costly character of AD: with the annual total cost per patient varying from 2,935 to 52,954 US dollars ($) [5]. The annual total costs increase with disease severity. Direct costs are associated with cognitive and functional status; the functional status is also associated with indirect costs [6]. Similar results were reported by another work of Jönsson that emphasized the need to standardize methods for assessing costs [7]. The aim of this paper was to offer an updated and systematic analysis of the literature on the costs related to AD and, in general, to adult-onset dementia disorders and on the tools used for their evaluation. Differently from previous review articles, we limited our analysis to clinical trials on the topic. The relevant limits found in the studies examined in terms of scarce consideration given to intangible costs are also highlighted. In conclusion, some methods which might be applied to acquire a better knowledge of AD s total cost are suggested. STUDIES SELECTION A systematic literature search was conducted on the PubMed and Medline databases using the following entries: direct costs in AD, indirect costs in AD, total costs in AD, intangible costs in AD and the MeSH terms listed below: Alzheimer Disease/economics, Cost of Illness/Alzheimer, Health Expenditures/Alzheimer, Health Care Costs/Alzheimer. Limits applied were: English language, at least one keyword corresponding to the above entries in the title/abstract, and study based on the evaluation of clinical trials. The analysis was carried out in November 2013 and included the 5-year period between 2008 and All articles were selected to obtain a costs evaluation of AD. Identified papers were further selected using the criteria of the Newcastle-Ottawa Scale that allows the assessment of the methodological quality of comparative studies and of case control studies. Overall study quality was defined as poor (score 0 4), moderate (5 6), or good (7 9) [8]. Excluded articles are summarized in Table 1. The main findings obtained in eligible studies were summarized in a tabular format. On the whole, we have found 4 papers for MeSH terms (Table 2) and 13 papers for others keys words such as direct costs, total costs, and indirect cost (Tables 3 and 4). REVIEW OF SELECTED STUDIES Patient-level cost of illness studies A summary of the most relevant features of the patient-level cost of illness studies analyzed is reported in Table 3. Gustavsson and coworkers [9] provided an empirical assessment of direct and indirect societal costs of AD using data collected through a survey carried out in four countries (Spain, Sweden, the United Kingdom, and the United States) and involving 1,222 patients. Direct and indirect costs were calculated by measuring the patients health care resource utilization during the 30 days before the visit. Medical care (AD medication, hospitalizations, emergency care, and outpatient care visits), community care (patient accommodation, respite care, and other community care services), and informal care were considered. Direct costs were calculated looking at the prices of resources that were consumed. Informal care value was considered the loss of productivity for the caregivers who gave up work to care for the patient and the value of leisure time for the remainder caregiving time. Mean cost estimates vary across countries and increase with the severity of disease for patients in community dwellings. Estimates range from 1,000 UK Pounds ( ) (real using the Purchasing Price Parity adjusted to the real exchange rates in 2007) per patient and month for mild patients living in the community, to 5,000 for patients living in residential care settings.

3 L. Colucci et al. / Costs of AD 1313 Table 1 List of papers excluded from analysis because they did not estimate the costs of AD Keyword Alzheimer/Economics Cost of Illness/Alzheimer Health Care Costs/Alzheimer Health Expenditures/Alzheimer Direct Costs/Alzheimer Indirect Costs/Alzheimer Total Costs/Alzheimer Articles excluded Van Houtven CH et al., Gerontologist, 2013 Pitkälä KH et al., JAMA Intern Med, 2013 Søgaard R et al., BMC Health Serv Res, 2009 Glueckauf RL et al., Rehabil Psychol, 2012 Frakey LL et al., J Clin Psychiatry, 2012 Cheng ST et al., Trials, 2012 Meeuwsen EJ et al., BMJ, 2012 Van Houtven CH et al., Gerontologist, 2013 Mohamed S et al., J Clin Psychiatry, 2012 Montgomery RJ et al., J Gerontol B Psychol Sci Soc Sci, 2011 Vreugdenhil A et al., Scand J Caring Sci, 2012 Martín-Carrasco M et al., Int J Geriatr Psychiatry, 2009 Lavretsky H et al., Am J Geriatr Psychiatry, 2010 Martin-Carrasco M et al., Aging Ment Health, 2010 Van Houtven CH et al., Gerontologist, 2013 Pitkala K et al., Trials, 2010 Kopits IM et al., Genet Test Mol Biomarkers, 2011 Pitkälä KH et al., JAMA Intern Med, 2013 Søgaard R et al., BMC Health Serv Res, 2009 Van Houtven CH et al., Gerontologist, 2013 Zhu CW et al., J Am Geriatr Soc, 2013 Frakey LL et al., J Clin Psychiatry, 2012 Van Houtven CH et al., Gerontologist, 2013 Bergvall N et al., Int Psychogeriatr, 2011 Voisin T et al., J Nutr Health Aging, 2010 Zhu CW et al., J Nutr Health Aging, 2009 Lachaine J et al., Can J Psychiatry, 2011 Glueckauf RL et al., Rehabil Psychol, 2012 Grammas P et al., J Neuroinflammation, 2011 Pfeil AM et al., Swiss Med Wkly, 2012 Chiatti C et al., Trials, 2013 Pitkälä KH et al., JAMA Intern Med, 2013 Mielke MM et al., Neurology, 2012 Cheng ST et al., Trials, 2012 Cummings JL, Neurobiol Aging, 2010 Wilson RS et al., Arch Neurol, 2010 Kunik ME et al., J Clin Psychiatry, 2010 Wolfs CA et al., Arch Gen Psychiatry, 2009 Zhu CW et al., J Am Geriatr Soc, 2013 Lin PJ et al., Med Care, 2009 A statistical analysis was carried out to identify the most important drivers of these costs. The main predictors were the disease severity measures [i.e. Mini-Mental State Examination (MMSE), Disability Assessment in Dementia (DAD), and Neuropsychiatric Inventory (NPI)]. These tests were used together with covariates such as patients characteristics, caregivers characteristics, and country fixed effects. The DAD was the most important predictor of costs of care of community dwelling patients. A one-point decrease on the DAD scale resulted in a 1.4 to 2% increase in costs on average, 32 or a 45% increase from a standard deviation decrease on DAD. NPI-severity and MMSE as well had a significant impact on costs but the effects sizes were smaller. Miller and coworkers [10] provided an estimation of AD direct costs using data collected through the Clinical Antipsychotic Trial of Intervention Effectiveness. Analysis was made in 42 sites in the United States involving 421 ambulatory outpatients with a diagnosis

4 1314 L. Colucci et al. / Costs of AD First Author Gustavsson [9] Miller [10] Coduras [15] Reese [17] Table 2 Papers evaluated for mesh terms Mesh terms Alzheimer Disease/economics Alzheimer Disease/economics Alzheimer Disease/economics Alzheimer Disease/economics of AD (MMSE 5 26) who lived with at least one caregiver. Data collection was longitudinal and each patient was interviewed three times over nine months. Interviews allowed to collect information concerning the patients use over the last 30 days of a wide variety of services, including nights spent in hospitals, nursing homes, and residential care facilities, other forms of community supports, mental health services, medical and surgical visits, and ancillary medications. All these services/goods were assigned a cost looking at unitary costs derived from published reports and administrative data sets in order to carry out the estimation of direct (health care system perspective) costs of AD. The results indicated an average of AD total direct costs of 1,205 US Dollars ($)/month per patient. Institutional care represented the 62.6% of monthly total costs; outpatient care the 20.1%; and ancillary drugs the 17.3%. In general, nursing home, residential care, and drug costs increased steadily through the 9 months considered, reflecting the progression of cognitive impairment as documented by average declines in MMSE and AD Cooperative Study Activities of Daily Living (ADCS-ADL). The authors also carried out a statistical analysis looking for covariates significantly related with the estimated total costs. A wide set of covariates, including measures of patients social-demographic characteristics, global cognitive functioning, psychiatric symptoms, physical functioning, quality of life, and quality of health, was assessed. Improvement of the individual health status as measured by the Health Utilities Index (HUI)-III, is associated with reduction in total costs. A one-point increase on the quality of life as measured by the AD-Related Quality of Life Scale (ADRQoL index) is significantly associated with increases in ancillary drug purchase and total costs. A rise of activities of daily living (as measured by the ADCS-ADL index) was significantly associated with declines in total costs. Gillespie and coworkers [11] estimated the costs of formal and informal care for AD using data gathered through the Enhancing Care in AD (ECAD) study [12]. Data were collected using structured questionnaires and medical assessments involving a sample of 100 Irish patients with AD or mild cognitive impairment interviewed in 2009 over a period of 6 months. Formal health and social care costs were calculated as resulting from general practice visits, hospitalizations, outpatient clinic consultations, accident and emergency visits, respite care, meals on wheels services, and additional health and social care professional consultations. All these services/goods were estimated using unit cost data calculated from a variety of national Irish data sources. Moreover, informal care costs were considered as resulting from caregiving hours provided by the primary carer for each patient, measured by the Resource Utilization in Dementia Lite (RUD) instrument [13]. Hours of informal care provided by employed carers were valued using the opportunity cost method whereas those provided by the unemployed were valued at opportunity cost of leisure time, proxied as a percentage (25%) of the average industrial wage per hour. The study reported that the average total cost for was 6,955 European Union Euros (D ) per patient over six months (1,845 D for health and social care plus 4,959 D for informal care, all data are expressed at 2008 currency value). A multivariate generalized linear model regression framework was adopted to explore the effects on total costs of a wide set of independent variables. Patient dependence measured by the dependence scale (DS), patient function (DAD scale), MMSE, and a range of other clinical and sociodemographic measures. The results show that both DS and DAD scores are positively and significantly associated with total cost over 6 months. Rapp and coworkers [14] used data drawn from the PLASA study (Plan de Soin et d Aide spécifique à la maladie d Alzheimer), a large randomized trial involving 1,131 patients with mild to moderate AD recruited between June 2003 and July 2005 from 50 French memory clinics. The data are longitudinal: each patient was interviewed three times over 2 years. The authors provide an estimation of AD total per patient cost as resulting from the sum of direct medical costs, direct non-medical costs, and informal costs. Direct medical and non-medical costs include the use of day care, alarm services, home help, and day/night surveillance. Medical costs included costs associated with inpatient and outpatient hospital visits, physician visits, speech therapist visits, physical therapist visits, nurse visits, and medication use. Informal costs arose from surveillance, Activities of Daily Living (ADL), and Instrumental Activities of Daily Living (IADL). During each interview, the use of the above resource/goods for the previous month was registered. The value of

5 L. Colucci et al. / Costs of AD 1315 Table 3 Studies considering the cost of the disease at the patient level considered. Summary of main features Authors Sample size Diagnosis used to select patients Gustavsson et al. [9] Miller et al. [10] Gillespie et al. [11] Rapp et al. [14] Coduras et al. [15] Herrmann et al. [16] 1,222 patients (Spain, Sweden, UK, USA) 421 patients (USA) 100 patients (Ireland) 1,131 patients (France) 560 patients (Spain) 903 patients (Canada) Clinical diagnosis of possible or probable AD. Dementia of the Alzheimer s type (DSM-IV) and probable AD. Diagnosis of probable or possible AD (according to the NINCDS-ADRDA criteria) or MCI (according to international consensus criteria) and aged >50 y. Diagnosis of AD mild or moderate. Diagnosis of possible or probable AD, consistent with DSM-IV or and NINCDS-ADRDA criteria. DSM-IV, diagnosis of dementia. Cost perspective Direct costs Indirect costs Type of analysis Tools for data collection Total cost estimate Societal Yes Yes Retrospective The Resource Use in Dementia (RUD) Lite questionnaire was used to interview the patients about their health care resource utilization during the 30 days before the visit. Health care system Yes No Perspective A structured questionnaire was used. Patients were interviewed three times over nine months and asked about the use of a wide variety of services over the last 30 days. Societal Yes Yes Perspective A structured questionnaire was used. Patients were interviewed over a period of 6 months. Societal Yes Yes Perspective The RUD 2.0 questionnaire was used. Patients were interviewed three times over 2 years. Societal Yes Yes Perspective The RUD questionnaire was used. Three visits: baseline, 6 and 12 months after inclusion in the study, with an additional visit 4 8 weeks after initiating the study. Societal Yes Yes Perspective Detailed resource use questionnaires were used. Patients were interviewed at baseline and every 6 months over a total of 36 months. UK 1,000/month per patient for mild patients living in the community (real pounds sterling using Purchasing Price Parity adjusted real exchange rates per 2007). UK 5,000 for patients living in residential care settings. $1,205/month per patient (2002 US $). EU D 6,955 per patient over six months (2008 Euros). EU D 1,845 for health and social care and EU D 4,959 for informal care. EU D 2,918/ month per patient at baseline, EU D 3,112/month per patient at year 1, and EU D 4,101/month per patient at year 2 (2007 euros). EU D 1,425.73/month per patient (2006 euros). It increased by 10.08% at the end of the study. C$367/month per patient for patients with very mild AD (GDS = 2), C$4,063/month per patient for patients with severe or very severe AD (2000 Canadian $).

6 1316 L. Colucci et al. / Costs of AD Table 3 (Continued) Authors Sample size Diagnosis used to select patients Reese et al. [17] Hurd et al. [18] Chhatrea et al. [19] 395 patients (Germany) 856 patients (USA) AD + CHF = 240 patients, AD only = 664, CHF only = 712, controls = 2,904 (USA) Diagnostic criteria for AD as defined by NINCDS-ADRDA Diagnosis of dementia determined with the use of a detailed in-home cognitive assessment. Diagnosis of AD (ICD , , 331.0) Cost perspective Direct costs Indirect costs Type of analysis Tools for data collection Total cost estimate Societal Yes Yes Retrospective Standardized questionnaires were used to collect data concerning all costs associated with AD that incurred over the prior three months. Yes Yes Perspective Questionnaire used is not specified. Data were extracted from the Health and Retirement Study, an American nationally representative longitudinal survey of persons. Health care system Yes No Retrospective Health resource utilization data and Medicare reimbursements (costs) for all care provided and paid for each person were extracted from databases such as the MEDPAR inpatient care, Outpatient Standard Analytical Files, home health and hospice care and carrier files. EU D 3,300 per patient for a three months period (2009 euros). Average annual cost is about EU D 13,080 per patient. $41,689/year per patient when the valuation of forgone wages was used to cost informal care (2010 US dollars) and $56,290/year per patient when the valuation of replacement cost was used to cost informal care. $20,888/y for AD + CHF group (2000 US dollars), $5473/y for only AD group, $17,700/y for only CHF group and $4,578/y for the control group (no-ad and no-chf). AD, Alzheimer s Disease; CHF, congestive heart failure; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; EU, European Union; ICD-9, International Classification of Diseases, 9th revision; MCI, mild cognitive impairment; MEDPAR, Medicare Provider Analysis and Review; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and the Stroke and Alzheimer s Disease and Related Disorders Association; RUD, Resource Use in Dementia; UK, United Kingdom; USA, United States of America.

7 L. Colucci et al. / Costs of AD 1317 Table 4 Studies considering the country-level cost of the disease considered. Summary of relevant features Authors Disease definition Cost perspective Luengo- Fernandez et al. [20] Wimo et al. [21] Wimo et al. [22] AD defined as International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) F00-F03 and G30. dementia as defined by the Eurocode group. dementia as defined by the World Alzheimer Report 2009 and the WHO dementia report Societal, (top-down) Countries considered Epidemiological approach The 15 EU countries in 2007: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden, UK. societal The 27 EU countries in 2008 Direct costs Indirect costs Total cost estimate Data sources Prevalence i) Health care costs ii) Social care costs iii) research funding Prevalence Resources used in the medical (e.g., hospital care) and non-medical (e.g., home help, nursing home care) sectors. societal Worldwide Prevalence Direct medical costs related to the medical care system, such as costs of hospital care, medication, and visits to clinics. Direct social care costs are for formal services provided outside of the medical care system, including community services such as home care, food supply, and transport, and residential or nursing home care. AD, Alzheimer s Disease; EU, European Union; UK, United Kingdom; WHO, World Health Organization. Opportunity cost of unpaid care, and valued in terms of the time that carers provide for their spouses, friends, or relatives suffering from dementia. Productivity losses due to mortality and morbidity Informal care (resource use and costs of caring for a demented person). Informal care (care input by family members, friends, and others). 189 billion D per year (2007 value) for the 15 EU countries considered; The corresponding annual per patient social care and healthcare cost is 9,904 D 160 billion D (2008 value) for the 27 EU countries considered. The corresponding per patient and year cost is 22,000 D 604 billion $ in 2010 (2010 value) The number of people with dementia in each of the EU-15 countries was obtained from a report published by Alzheimer s Disease International. Data concerning resources use and costs were extracted from EUROSTAT and country-specific studies. Data on the number of people affected by dementia in each country were drawn from a meta-analysis carried out by the Eurocode group. Country-specific per-capita direct and indirect cost data were extracted from fourteen papers from key countries. Missing data were imputed. Number of people affected by dementia in a number of regions of the world drawn from the World Alzheimer Report 2009 and the dementia report by the WHO. Country-specific per-capita direct and indirect cost data are extracted from a detailed literature review. Missing data were imputed.

8 1318 L. Colucci et al. / Costs of AD resources included in direct costs was calculated using unit costs collected using the French consumer price index. The replacement wage method was applied to calculate costs of informal caregiving, assuming that the unit cost was equal to the average hourly wage in French private industries. The mean total cost of AD per month was 2,918 D at baseline, 3,112 D at year 1, and 4,101 D at year 2. Informal cost was the largest component per month, and its importance in total costs increased over time from 2,334 D at baseline, to 2,510 D at year 1, and 3,373 D at year 2. Regression analyses were carried out in order to explore the determinants of total costs. Covariates included cognitive status (measured by MMSE), functional status measured by the Katz Index of Independence in Activities of Daily Living (Katz ADL scale), the severity and frequency of a wide range of behavioral reactions measured by the NPI, sociodemographic variables such as patients age, gender, education level, time since AD diagnosis, and informal caregivers subjective burden measured by the Zarit Burden Interview index (ZBI). Possible biases in assessing relationship between MMSE, ADL, NPI, ZBI and AD costs were evaluated by estimation of instrumental variables. For these calculations lagged value of total costs, patients level of education, and a categorical variable measuring whether another informal caregiver provided help rarely, sometimes, or always, were considered. The study showed that the most important predictors of costs were functional and cognitive declines. A marginal decrease in MMSE score was associated with a 7% increase in total costs while a marginal loss in ADL was associated with a 28.65% increase in total costs. Caregivers subjective burden and the severity and frequency of behavioral reactions were found to be slightly positively associated with total costs. The study highlighted that the relationship between MMSE and costs could lead to a large underestimation of the impact of MMSE on costs, being a marginal decrease in MMSE score associated with a 29.30% increase in the total cost of care. Coduras and coworkers [15] used data drawn from the ECO study which is a multi-center, prospective, 12- month, observational study, conducted in Spain between 2003 and This study involved 560 patients at different stages of AD who were interviewed in three different dates over the time of the trial. The analysis has calculated AD direct costs resulting from the use of healthcare resources (medical visits, drugs and concomitant treatments, complementary and diagnostic tests, institutionalization, and use of home-nursing facilities) and non-healthcare resources (inventory materials, consumables, professional and non-professional caregivers time for care and supervision) assessed according to 2006 prices taken from the Pharmacist Colleges General Council catalogue for drugs. Indirect costs were also computed, with the substitution costs method being applied by multiplying the number of days of work absence in the case of informal caregivers by the mean salary earning declared by the caregiver. Monthly average costs per patient were 1, D, and increased by the 10.08% at the end of the study. Non-healthcare costs (1,059 D being the 74.30% of total cost) decreased by 4.30 D /month (0.40%) at the end of the year, while healthcare costs, which presented a total average of D, increased by D at the time of observation (54.06%), mainly due to cost of drugs, nursing home utilization, and institutionalization. The caregivers total burden represented 70.86% of the overall cost of illness. A statistical analysis was also carried out to investigate how monthly progression of costs over the course of the study is linked to a wide set of caregiver-specific sociodemographic covariates such as age, gender, marital status, living arrangements, years of education, level of education, and income. Analysis included a wide set of clinical variables such as Clinical Dementia Rating Scale (CDR), Blessed Dementia Rating Scale (BDRS), Health Utilities Index-Mark 3 (HUI-3), ZBI, and MMSE. The results showed that when the caregiver is the spouse or partner, divorced/separated, or has a university level of education, the monthly cost is higher. In terms of clinical variables, the MMSE and mainly the BDRS scores showed a statistically significant effect on the average monthly cost. The CDR and HUI-3 scales and the ZBI did not correlate significantly with costs. Herrmann and coworkers [16] analyzed data collected during the Canadian Outcomes Study in Dementia (COSID), a prospective observational study conducted in Canada between 2000 and 2003 involving 903 dementia-diagnosed patients and their caregivers who were interviewed at baseline and every 6 months over a total of 36 months. The authors adopted a societal perspective assessment and estimated both direct (medical and non-medical) and indirect costs of AD. Direct costs result from expenditures for visits to a family doctor, general practitioner, specialist, day surgery, psychiatric nurse, home care nurse, counselor or psychologist, laboratory or diagnostic tests, hospitalizations, support group, meals on wheels, etc. The use of these resources was registered using detailed questionnaires and valued by prices extracted from a

9 L. Colucci et al. / Costs of AD 1319 comprehensive cost dictionary considering many service providers. Medication costs were obtained from a British Columbia-based wholesale pharmacy 2000 price list. Indirect costs were calculated by determining the number of days the patient and (or) caregiver was prevented from performing their regular activities and determining the market value of the informal care provided by looking at the data provided by the Canada Statistics 1997 on domestic help hourly wage. The results showed that total costs are significantly higher with greater disease severity. The mean total cost to treat patients with very mild AD (Global Deterioration Scale (GDS) = 2) was 367 Canadian Dollars (C$) per month (value of the currency in 2000), compared with 4,063 C$ per month for patients with severe or very severe AD (GDS = 6). The largest component of total cost was represented by indirect costs. Medication costs were more relevant in patients with very mild AD. A statistical analysis revealed that female gender, poorer function, and more neuropsychiatric symptoms are significant predictors of total cost. A wide set of severity measures such as GDS, MMSE, and Functional Autonomy Measurement System (SM AF) showed a highly significant positive association with total costs of AD. Reese and coworkers [17] used data gathered through a cross-sectional survey done in 2009 involving 395 patients who were recruited in the region of Marburg-Biedenkopf in Germany. Recruited subjects were asked for a retrospective evaluation of the costs incurred over the prior three months. The study estimated total, direct, and indirect cost of AD. Direct costs included outpatient care, inpatient care, drug costs, and costs of nursing home. The use of health care resources by patients was recorded through standardized questionnaires. Calculation of the costs of outpatient care was based on the cost values related to specialists. Costs for inpatient care were calculated based on the mean daily costs for the specific departments. Drugs costs were calculated on the basis of the official German price list of drugs. Costs for patients living in nursing homes were obtained from the official tariff lists published by each institution. Finally, indirect costs were calculated both for patients and caregivers in terms of productivity losses due to a) early retirement, b) inability to work, c) unemployment, d) sick leave, and e) reduction of labor time caused by AD. Using the human capital approach, costs due to productivity lost were calculated on the basis of the Statistical Year Book 2009 for the Federal Republic of Germany. The average total cost for a three-month period was approximately 3,300 D (2009 value) and the average annual cost was about 13,080 D. The total annual costs was approximately 25,500 D in patients living in longterm care facilities and 7,450 D for patients still living at home. The most important cost component was long-term care, constituting about 43% of total costs. Indirect costs represented about the 18% of total costs and were mainly due to reductions in working time of caregivers. A bivariate and multivariate analysis was made to estimate empirically the effects of a number of clinical characteristics, such as depression (measured by Geriatric Depression Scale), general cognition measured by MMSE and Alzheimer s Disease Assessment Scale (ADAS-Cog), activities of daily living (ADCS- ADL), neuropsychiatric symptoms (measured by NPI) on the total cost of illness. The study concluded that impaired activities of daily living (ADCS-ADL) are the most important predictor of costs. Hurd and coworker [18] provided an estimation of monetary costs of dementia based on 2010 data collected from a subsample (856 persons) of the population involved in the Health and Retirement Study, a nationally representative prospective study carried out in the US from The market costs associated with care for persons with dementia were determined on the basis of self-reported out-of-pocket spending (e.g., nursing home stays, hospital stays, medical visits, outpatient surgery etc.), spending recorded by the Federal Government social insurance program Medicare (e.g., durable-medical-equipment purchases, skilled nursing-facility care), spending for home nursing and for formal/ informal home care. Informal care was evaluated using a replacement cost approach and, alternatively, by means of the forgone wage approach. To isolate the costs directly attributable to dementia from those due to other coexisting diseases, authors used a multivariate regression model relating cost components to the patients predicted probability of dementia (calculated according to personal and household characteristics), to coexisting conditions and to a set of demographic characteristics. The results indicate that attributable yearly cost per person, including those of care purchased in the marketplace and those cost of informal care, were 41,689 $ (2010 values) when the evaluation of forgone wages was used and 56,290 $ when the evaluation of replacement cost was used. The main component of the costs attributable to dementia is the cost for institutional and home-based long-term care rather than the costs of medical services. Calculating the value of informal home care in terms of forgone wages yielded an estimate of the cost of unpaid caregiving that was 31% of the total cost. Calculation of the value of informal

10 1320 L. Colucci et al. / Costs of AD home care in terms of the replacement cost yielded an estimate of 49%. Chhatrea and coworkers [19] provided a retrospective case-control study whose aim was to assess health resource utilization and direct cost of care in the elderly with AD and with or without concomitant congestive heart failure (CHF). A group of 904 patients with a diagnosis of AD and an AD free control group (n = 3,616) were recruited for this study over 1999 and 2000 in the US. The AD and non-ad groups were further subdivided into those with and without a diagnosis of CHF (AD + CHF = 240 patients), AD only (664 patients), CHF only (712 patients) and control group (2,904 patients). Data were gathered through an administrative database of a large urban academic health care system (PICARD). Authors obtained data of health care resources utilization data and Medicare reimbursements for inpatient costs, outpatient costs, inpatient pharmacy costs, length of stay, number of emergency room visits, number of inpatient admissions, number of outpatient visits, number of diagnostic, lab procedures, and home health and hospice care. All these data were extracted from databases such as the Medicare Provider Analysis and Review (MEDPAR) inpatient care, Outpatient Standard Analytical Files (SAF) home health and hospice care and carrier files. The study calculated a mean annual cost of 20,888 $ (2007 value) for the AD- CHF group, 5,473 $ for the AD-only group, 17,700 $ for the CHF-only group, and 4,578 $ for the control group (no-ad and no-chf). Hence, the direct cost of AD was higher than the one observed for the control group, but the total cost of caring for persons with CHF alone was higher. As expected, a co-occurring diagnosis of AD and CHF is accompanied by substantial increases in all medical care costs, mainly inpatient care. Log-linear regressions were run in order to investigate the impact on costs of a number of personal variables such as age, race, gender, subsample epidemiology (AD only, CHF only, AD+CHF, control group) and co-morbidity. Compared with the reference group (control group), the total cost for those belonging to the AD + CHF group were 8-fold higher, while for those belonging to the CHF-only group it was 5-fold higher and co-morbidity had an obvious effect on total costs rise. Country-level cost of illness studies The most relevant features of the country-level cost of illness studies analyzed are summarized in Table 4. Luengo-Fernandez and coworkers [20] provided estimates of the societal perspective economic burden of AD across the 15 European Union member states in In this study, which adopted a prevalence approach, AD was defined according to the International Statistical Classification of Diseases and Related Health Problems (10th Revision). Data on the number of dementia patients were extracted from a report published by Alzheimer s Disease International. Cost estimations are based on patient-level studies and aggregate data on morbidity, mortality, health and social care use extracted from various sources. Five typologies of costs were considered: i) health care costs: primary care (dementia-related visits to general practitioners, together with general practitioner visits to patients homes, and visits to or by a primary care nurse); accident and emergency care (dementia-specific hospital emergency visits); hospital outpatient care (specialist consultations taking place in outpatient wards, clinics, or patients homes); hospital inpatient care; and medications. To account for private expenditure on health care in countries where data was only available on public expenditure, cost estimates were inflated using the total proportion of private expenditure on health care; ii) social care costs (number of dementia-related weeks spent in care homes); iii) informal care costs as resulting from country-specific data on the time spent by relatives and friends providing unpaid care for dementia patients multiplied for caregivers wages; iv) productivity losses due to mortality and morbidity. These are valued by looking at value. The number of working years lost due to premature mortality was estimated using expected working years left by age group and the number of deaths stratified by age and gender; and v) governments and charities expenditure for research funding in the European Union 15 countries as resulting from data published by the Resource Allocation to Brain Research in Europe study (RABRE). The resulting total annual cost of dementia is 189 billion D per year (2007 euros) for the 15 countries considered. Social care services are 49 billion D, 26% of total cost, whereas healthcare costs accounted for 10 billion D (5%). The corresponding annual per patient social care and healthcare cost is 9,904 D. Informal care accounted for 105 billion D, 64% of total cost, representing 11.9 billion hours of unpaid care provided by relatives and friends of dementia patients. Productivity losses, including mortality and morbidity losses, accounted for 2.2 billion D, only 1% of total cost, mainly because dementia occurs in old non-working patients. Moreover, the study shows that cost compo-

11 L. Colucci et al. / Costs of AD 1321 sition significantly varies across European countries. The proportion of total costs due to informal care is about 75% in in Southern European countries while it represents around 50% of total costs in Northern countries where long-term institutional care is significantly higher. Wimo and coworkers [21] published an empirical study whose aim is to calculate the societal, prevalence-based total economic impact of dementia in the 27 countries part of the European Union in Data on the number of people affected by dementia in each country was drawn from the a meta-analysis carried out by the Eurocode group while country-specific per-capita direct (medical, e.g., hospital care, and nonmedical, e.g., home help, nursing home care sectors) and indirect (informal care) cost data was extracted from a detailed literature review including fourteen papers from key countries. Imputation was used for countries where no cost figures were available. The total estimated cost of dementia in the 27 countries of the European Union in 2008 is 160 billion D,of which 56% are costs of informal care. The corresponding per patient and year cost is 22,000 D. Consistent with the paper by Luengo-Fernandez et al. [20], the results show that in Northern Europe the direct costs are considerable while in southern Europe the major cost component is the one related to the informal care. The latter study was updated by Wimo and coworkers [22] who have done a societal, prevalence based estimation of total costs of dementia worldwide. In this study the authors use data on the number of people affected by dementia in a number of regions of the world drawn from the World Alzheimer Report 2009 and the dementia report by the World Health Organization. Following their previous paper [21], country-specific per-capita direct and indirect cost data are extracted from a detailed literature review and imputed in case of missing country information. Direct medical costs were considered those of hospital care, medication, and visits to clinics. Direct social care costs include formal services provided outside of the medical care system, including community services such as home care, food supply, and transport, and residential or nursing home care. Finally, informal costs concern care input by family members, friends, and others. The total estimated worldwide costs of dementia is 604 billion $ in The costs are distributed unevenly: about 70% of them occurred in western Europe and North America. In such high-income regions, costs of informal care and the direct costs of social care contribute similar proportions of total costs (40 45%), while the direct medical costs were much lower. In low and middle-income countries the majority of costs are related to informal care accounts while direct costs are negligible. DISCUSSION What do we know? The evaluation of AD costs allows us to understand the extent of the present economic burden of illness to society and to predict its dimension in the near future, when the number of patients will significantly increase [3]. AD is only one of a number of diseases leading to dementia, which may also be due to other neurodegenerative disorders such as frontotemporal dementia, Lewy body disease, vascular dementia, and other less frequent forms of adult-onset dementias. Dementia is, in fact, an umbrella term under which different pathologies are grouped. However, a neat clinical differentiation of AD by other disorders is difficult in many cases, and AD is by far the most frequent adultonset dementia. Consequently, our review has included papers that estimate costs associated to AD (8 papers) [9 11, 14, 15, 17, 19, 20], together with those investigate costs of dementia more generally speaking (4 papers) [16, 18, 21, 22]. The same approach is adopted by the majority of review articles published in this field [7, 23, 24]. As already mentioned above, 9 papers provided a patient-level estimation of costs [9, 14 19] while 3 [20 22] focused on the investigation of country-level cost of the disease. Among the papers we reviewed, 10 adopted a societal perspective [9, 11, 14 18, 20 22] and 2 [10, 19] adopted a health care system perspective. Only one study [20] adopted a top-down approach in estimating the total cost of illness; all the other studies rely on data collected through interviews with patients who were asked about the quantity of health inputs used. Among these latter studies, the majority employs standard questionnaires, such as the RUD questionnaire, to collect data through interviews. Most of the studies estimate both direct and indirect costs. The only exceptions are represented by Miller and coworkers [11] and Chhatrea and coworkers [19] who centered their analysis on direct costs. Analysis of the studies that provide patient-level total (direct + indirect) cost of illness estimates, showed that the cost per patient and month is highly variable; ranging from 347 C$ for patients with very mild AD [16] to 4,690 $ for the American patients [18]. Looking at

12 1322 L. Colucci et al. / Costs of AD European studies, the lowest cost per patient and month is reported by the German study [17] which found a value of 1,100 D (monetary value similar to the one found by the Irish study [11]. The highest is calculated by the French study [14] who registered a mean total cost of 2,918 D per patient and month. The variability of costs depends, at least partially, by different voices of direct and indirect costs included in the studies reviewed. In the French study [14], the direct costs refer to day care, hospital and physicians visits, medical treatments, and expenses due to speech and physical therapists; the Spanish study, instead, apart from the day care and the medical and nurse interventions, also includes the institutionalization. On the other hand, some studies consider as indirect costs the loss of productive of patients and caregivers [17], but others studies include only the lost production for the caregivers [9]. The same variability is found when looking at country-level estimates. Ten studies (83% of the papers examined) report the relative contribution of the direct and indirect costs to the total amount [9, 11, 14 18, 20 22] while 2 studies are without this differentiation [11, 19]. Direct and indirect costs (and therefore total costs) are very high in AD and their distribution changes during the progression of disease. Informal cost is the largest cost component and these costs increase over the time [14, 16, 20 22]. In the US, the mean of direct costs is 1,205 $/month per patient [10]. In Europe the mean of direct costs seems to be inferior than in the US (about 800 D /month per patient) [17, 20]. In terms of indirect costs, the mean of cost per patient and month in Europe is about 500 D [17] while in the US the same costs are apparently higher (about 1,000 $/month per patient) [18]. Different variables are found to be significant determinants of cost. Cognitive decline represents an important variable in the costs rise, and its severity causes higher costs [11, 14 16]. MMSE, and more generally the score of cognitive tests (as GDS, ADAS-Cog) [16, 17] allowing an objective evaluation of the cognitive impairment over time, are the most used cognitive variables. Costs vary according to the loss of autonomy of the patients, and thus to the results of the functional scales [11, 25], the most employed being the SM AF-B ADL [16], the DS [11], the DAD [9], the BDRS [15], and the ADL [14]. The DAD is indicated as the most important predictor of the costs of care [9], of total costs [11], and of caregiver time [25], while the DS is significantly related with total costs [11]. The BDRS and the SM AF are also important predictors of total costs [15, 16], while the ADL is associated with both total cost and medical and non-medical costs [14]. Recently introduced scales to evaluate the caregivers burden, as the ZARIT, are useful in measuring this determinant variable of indirect costs [14]. What should we know better? The evaluation of the intangible costs is a missing aspect in all reviewed studies, none of which has specifically indicated them. However, the pain, anxiety and other factors such as the difficulty in maintaining personal relationships, or having leisure time, can negatively influence the quality of life of both caregivers and patients, thus constituting an aspect that should be accurately taken into account. Specific methodologies have been developed to this aim. Some, as the Health-Related Quality of Life, have been essentially designed to evaluate the impact of the informal caregiving on caregivers health [26]. Others, such as the EuroQoL [27], and the Care-Related Quality of Life (CarerQoL) [28], are aimed at measuring a more comprehensive aspect, that is the well-being (happiness) of the caregivers in relationship to their activity. Well-being is a wider concept than health, and seems more adequate to capture the complexity of the effects related to the caregiving. Furthermore, the CarerQoL includes within its numerous dimensions the level of the satisfaction that may derive from the giving of care, an aspect often reported by the caregivers, to which this tool assigns, thus, a fair value. The Caregivers Quality of Life Index is quite a similar instrument, which evaluates three standard dimensions of the caregiving, but which has a higher complexity [29]. The Caregiver Burden Inventory, an easy questionnaire aimed at evaluating the psychological, physical, social and emotional aspects of the caregiving, is a well-known and widely applied measure which takes into account the objective and the subjective aspects of care [30]. Subjective aspects, which refer to the caregiver s perception of their own caring activity, have been particularly highlighted by other instruments as the Caregiver Strain Index [31], the Caregiver Reaction Assessment [32] and the Sense of Competence [33]. These instruments are however more designed to register than to measure the burden, so that they should be first translated into monetary terms. The Self-Rated Burden [34] includes also an evaluation measure. The intangible costs as well refer to the patients, even if the assessment of their quality of life by ques-

Accepted 26 March 2013

Accepted 26 March 2013 Journal of Alzheimer s Disease 36 (2013) 385 399 DOI 10.3233/JAD-122392 IOS Press 385 The GERAS Study: A Prospective Observational Study of Costs and Resource Use in Community Dwellers with Alzheimer s

More information

Cost of Disorders of the Brain in Europe Gustavsson et al. Cost of disorders of the brain in Europe Eur. Neuropsych. (2011) 21,

Cost of Disorders of the Brain in Europe Gustavsson et al. Cost of disorders of the brain in Europe Eur. Neuropsych. (2011) 21, Cost of Disorders of the Brain in Europe 2010 Gustavsson et al. Cost of disorders of the brain in Europe 2010. Eur. Neuropsych. (2011) 21, 718-779 Steering Committee Prof Jes Olesen 1 Prof Bengt Jönsson

More information

European Collaboration on Dementia. Luxembourg, 13 December 2006

European Collaboration on Dementia. Luxembourg, 13 December 2006 European Collaboration on Dementia Luxembourg, 13 December 2006 2005 Call for projects Special attention has also to be given to information and definition of indicators on neurodegenerative, neurodevelopment,

More information

Hana Ross, PhD American Cancer Society and the International Tobacco Evidence Network (ITEN)

Hana Ross, PhD American Cancer Society and the International Tobacco Evidence Network (ITEN) The Costs of Smoking Hana Ross, PhD American Cancer Society and the International Tobacco Evidence Network (ITEN) Why Do We Study the Cost of Smoking? To assess the economic impact of smoking behavior

More information

K. Kahle-Wrobleski 1, J.S. Andrews 1, M. Belger 2, S. Gauthier 3, Y. Stern 4, D.M. Rentz 5, D. Galasko 6

K. Kahle-Wrobleski 1, J.S. Andrews 1, M. Belger 2, S. Gauthier 3, Y. Stern 4, D.M. Rentz 5, D. Galasko 6 The Journal of Prevention of Alzheimer s Disease - JPAD Volume 2, Number 2, 2015 Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimer s Disease: Transforming Functional

More information

INFORMAL CARE COST AND OUT-OF-POCKET PAYMENT TO SUPPORT PEOPLE WITH DEMENTIA: THEIR MICRO-LEVEL DETERMINANTS IN A LARGE

INFORMAL CARE COST AND OUT-OF-POCKET PAYMENT TO SUPPORT PEOPLE WITH DEMENTIA: THEIR MICRO-LEVEL DETERMINANTS IN A LARGE + INFORMAL CARE COST AND OUT-OF-POCKET PAYMENT TO SUPPORT PEOPLE WITH DEMENTIA: THEIR MICRO-LEVEL DETERMINANTS IN A LARGE SAMPLE SURVEY IN JAPAN Takayo Nakabe 1, Noriko Sasaki 1, Hironori Uematsu 1, Susumu

More information

Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary

Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease Summary Mai 17 th 2017 Background Alzheimer s disease is a serious neurocognitive disorder which is characterized

More information

Key Highlights continued

Key Highlights continued Financing the Response to AIDS in Low- and Middle- Income Countries: International Assistance from the G8, European Commission and Other Donor Governments in 2009 Authors: Jennifer Kates (Kaiser Family

More information

The health economic landscape of cancer in Europe

The health economic landscape of cancer in Europe 1 Approval number The health economic landscape of cancer in Europe Bengt Jönsson, Professor Emeritus of Health Economics Stockholm School of Economics 2 Disclaimer This presentation was developed by Professor

More information

Tobacco Health Cost in Egypt

Tobacco Health Cost in Egypt 1.Introduction 1.1 Overview Interest in the health cost of smoking originates from the desire to identify the economic burden inflicted by smoking on a society. This burden consists of medical costs plus

More information

The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-topay

The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-topay The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-topay approach Wu G, Lanctot K L, Herrmann N, Moosa S, Oh P I Record Status This is a critical abstract of an economic

More information

Authors: Jennifer Kates (Kaiser Family Foundation), Eric Lief (The Stimson Center), Carlos Avila (UNAIDS).

Authors: Jennifer Kates (Kaiser Family Foundation), Eric Lief (The Stimson Center), Carlos Avila (UNAIDS). Financing the response to AIDS in low- and middleincome countries: International assistance from the G8, European Commission and other donor Governments in 2008 Authors: Jennifer Kates (Kaiser Family Foundation),

More information

Prospective One-Year Cost-of-Illness Study in a Cohort of Patients with Dementia of Alzheimer s Disease Type in Spain: The ECO Study

Prospective One-Year Cost-of-Illness Study in a Cohort of Patients with Dementia of Alzheimer s Disease Type in Spain: The ECO Study Journal of Alzheimer s Disease 19 (2010) 601 615 601 DOI 10.3233/JAD-2010-1258 IOS Press Prospective One-Year Cost-of-Illness Study in a Cohort of Patients with Dementia of Alzheimer s Disease Type in

More information

Authors: Jennifer Kates (Kaiser Family Foundation), José-Antonio Izazola (UNAIDS), Eric Lief (CSIS).

Authors: Jennifer Kates (Kaiser Family Foundation), José-Antonio Izazola (UNAIDS), Eric Lief (CSIS). Financing the response to AIDS in low- and middleincome countries: International assistance from the G8, European Commission and other donor Governments, 2006 Authors: Jennifer Kates (Kaiser Family Foundation),

More information

A COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH:

A COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH: A COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH: Amputee Coalition of America Mended Hearts National Federation of the Blind National Kidney Foundation

More information

RESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH

RESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of

More information

Behavioral Health Hospital and Emergency Department Health Services Utilization

Behavioral Health Hospital and Emergency Department Health Services Utilization Behavioral Health Hospital and Emergency Department Health Services Utilization Rhode Island Fee-For-Service Medicaid Recipients Calendar Year 2000 Prepared for: Prepared by: Medicaid Research and Evaluation

More information

Alzheimer s disease affects patients and their caregivers. experience employment complications,

Alzheimer s disease affects patients and their caregivers. experience employment complications, Alzheimer s Disease and Dementia A growing challenge The majority of the elderly population with Alzheimer s disease and related dementia are in fair to poor physical health, and experience limitations

More information

Setting The setting was institutional and tertiary care in London, Essex and Hertfordshire in the UK.

Setting The setting was institutional and tertiary care in London, Essex and Hertfordshire in the UK. Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis Knapp M, Thorgrimsen L, Patel A, Spector A, Hallam A, Woods B, Orrell M Record Status This is a critical abstract of

More information

Financing the Response to AIDS in Low- and Middle- Income Countries: International Assistance from Donor Governments in 2011

Financing the Response to AIDS in Low- and Middle- Income Countries: International Assistance from Donor Governments in 2011 Financing the Response to AIDS in Low- and Middle- Income Countries: International Assistance from Donor Governments in 2011 Authors: Jennifer Kates (Kaiser Family Foundation), Adam Wexler (Kaiser Family

More information

Study population The study population comprised adult patients fulfilling the following inclusion criteria:

Study population The study population comprised adult patients fulfilling the following inclusion criteria: Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy McCrone P, Chisholm D, Knapp M, Hughes R, Comi G, Dalakas M C, Illa I,

More information

The burden and cost of cancer

The burden and cost of cancer 18 (Supplement 3): iii8 iii22, 2007 doi:10.1093/annonc/mdm097 The burden and cost of cancer summary The incidence of cancer is increasing and the reasons for this are multifactorial. With respect to mortality,

More information

Setting The setting was primary care. The economic study was carried out in Brazil, France, Germany and Italy.

Setting The setting was primary care. The economic study was carried out in Brazil, France, Germany and Italy. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model Aballea S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, Toniolo-Neto J, Drummond M, Weinstein

More information

A pan-european study on outcome measures for psychosocial intervention research in dementia

A pan-european study on outcome measures for psychosocial intervention research in dementia A pan-european study on outcome measures for psychosocial intervention research in dementia CHATTAT Rabih, MONIZ-COOK Esme, WOODS Bob, and members of the INTERDEM JPND outcomes working group 26 th Alzheimer

More information

Population Characteristics

Population Characteristics Heights River Heights 1 The River Heights Community Area (CA) is one of 12 community areas (CAs) in the Winnipeg Health Region (WHR). A population health profile has been generated for the River Heights

More information

Paying to Die. The Economic Burden of Care Faced by Patients and Their Caregivers. 5th EAPC Research Forum, Trondheim May, 2008

Paying to Die. The Economic Burden of Care Faced by Patients and Their Caregivers. 5th EAPC Research Forum, Trondheim May, 2008 Paying to Die The Economic Burden of Care Faced by Patients and Their Caregivers Konrad Fassbender, PhD. Division of Palliative Care Medicine University of Alberta 5th EAPC Research Forum, Trondheim 28-31

More information

Societal, pharmacotherapeutic and policy aspects of dementia care in Malta

Societal, pharmacotherapeutic and policy aspects of dementia care in Malta Societal, pharmacotherapeutic and policy aspects of dementia care in Malta Charles Scerri Department of Pathology, University of Malta 20 th Alzheimer Europe Conference Facing dementia together Luxembourg,

More information

The prevalence, economic cost and research funding of dementia compared with other major diseases. Executive summary

The prevalence, economic cost and research funding of dementia compared with other major diseases. Executive summary DEMENTIA 2010 The prevalence, economic cost and research funding of dementia compared with other major diseases Executive summary A report produced by the Health Economics Research Centre, University of

More information

VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION

VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION A snapshot of data on amoxicillin, budesonide, losartan and salbutamol in eight European Union Member States Report INTRODUCTION

More information

Systematic review: the costs of ulcerative colitis in Western countries

Systematic review: the costs of ulcerative colitis in Western countries Alimentary Pharmacology & Therapeutics Systematic review: the costs of ulcerative colitis in Western countries R.D.COHEN*,A.P.YU, E.Q.WU, J.XIE, P.M.MULANIà &J.CHAOà *Department of Medicine, Section of

More information

Paying for Dementia Care. Mary Ann Forciea MD Clinical Professor of Medicine Division of Geriatric Medicine University of Pennsylvania Health System

Paying for Dementia Care. Mary Ann Forciea MD Clinical Professor of Medicine Division of Geriatric Medicine University of Pennsylvania Health System Paying for Dementia Care Mary Ann Forciea MD Clinical Professor of Medicine Division of Geriatric Medicine University of Pennsylvania Health System Audience: Possible concerns about dementia care in my

More information

Financing the Response to AIDS in Low- and Middle- Income Countries: International Assistance from Donor Governments in 2010

Financing the Response to AIDS in Low- and Middle- Income Countries: International Assistance from Donor Governments in 2010 Financing the Response to AIDS in Low- and Middle- Income Countries: International Assistance from Donor Governments in 2010 Authors: Jennifer Kates (Kaiser Family Foundation), Adam Wexler (Kaiser Family

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Atri A, Frölich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on in cognition in patients with Alzheimer disease: three randomized clinical

More information

Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study René Thyrian

Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study René Thyrian Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study René Thyrian German Center for Neurodegenerative Diseases (DZNE), site

More information

Across the Cognitive Impairment Continuum Increasing Patient Dependence is Associated with an Increase in Caregiver Burden

Across the Cognitive Impairment Continuum Increasing Patient Dependence is Associated with an Increase in Caregiver Burden Across the Cognitive Impairment Continuum Increasing Patient Dependence is Associated with an Increase in Caregiver Burden Loretto Lacey Janssen Alzheimer s Immunotherapy Dublin, Ireland Alzheimer's Europe

More information

ABSTRACT. Keywords: Alzheimer s disease; Informal caregiver; Time and costs ORIGINAL RESEARCH

ABSTRACT. Keywords: Alzheimer s disease; Informal caregiver; Time and costs ORIGINAL RESEARCH Neurol Ther (2017) 6:11 23 DOI 10.1007/s40120-016-0056-2 ORIGINAL RESEARCH Informal Care Time and Cost in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer s Disease: Determinants

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal

More information

ETHIOPIA S HOUSEHOLD HEALTH SERVICES UTILIZATION AND EXPENDITURE SURVEY

ETHIOPIA S HOUSEHOLD HEALTH SERVICES UTILIZATION AND EXPENDITURE SURVEY Federal Democratic Republic of Ethiopia Ministry of Health ETHIOPIA S HOUSEHOLD HEALTH SERVICES UTILIZATION AND EXPENDITURE SURVEY BRIEFING NOTES April 2014 Recommended Citation: Ethiopia Federal Ministry

More information

Joint Programming in Neurodegenerative Disease Research (JPND)

Joint Programming in Neurodegenerative Disease Research (JPND) Joint Programming in Neurodegenerative Disease Research (JPND) Building Alliances and Collaborations Prof. Philippe Amouyel, MD, PhD JPND Chair France Disclosure CEO of Fondation Plan Alzheimer Conference

More information

Extrapolation and potential impact of IPHS deployment in Europe

Extrapolation and potential impact of IPHS deployment in Europe SIMPHS2 Validation Workshop Brussels, 31 Jan 2012 1 SIMPHS2 Validation Workshop Extrapolation and potential impact of IPHS deployment in Europe JRC IPTS IS Unit Ioannis Maghiros, Fabienne Abadie, Maria

More information

THE CVD CHALLENGE IN NORTHERN IRELAND. Together we can save lives and reduce NHS pressures

THE CVD CHALLENGE IN NORTHERN IRELAND. Together we can save lives and reduce NHS pressures THE CVD CHALLENGE IN NORTHERN IRELAND Together we can save lives and reduce NHS pressures The challenge of CVD continues today. Around 225,000 people in Northern Ireland live with the burden of cardiovascular

More information

Brazil Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen, Denmark, October 2018

Brazil Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen, Denmark, October 2018 Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen,, October 2018 LEO Innovation Lab in cooperation with The Happiness Research Institute, 2018. All rights reserved. Any part of

More information

American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline

American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline I. Geriatric Psychiatry Patient Care and Procedural Skills Core Competencies A. Geriatric psychiatrists shall

More information

The accident injuries situation

The accident injuries situation Appendix 2. The accident injuries situation Almost 90 % of injury deaths take place in home and leisure Almost 80 % of accidents leading to injury take place in home and leisure Unintentional injuries

More information

Memorias Convención Internacional de Salud Pública. Cuba Salud La Habana 3-7 de diciembre de 2012 ISBN

Memorias Convención Internacional de Salud Pública. Cuba Salud La Habana 3-7 de diciembre de 2012 ISBN Primary Health Care and the Management of the Ambulatory Care Sensitive Conditions of Hypertension and Diabetes in Jamaica Charlton McFarlane Ministry of Health and University of the West Indies and Natalie

More information

The place for treatments of associated neuropsychiatric and other symptoms

The place for treatments of associated neuropsychiatric and other symptoms The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public

More information

Cost-Motivated Treatment Changes in Medicare Part B:

Cost-Motivated Treatment Changes in Medicare Part B: Cost-Motivated Treatment Changes in Medicare Part B: Implications for Non- Medical Switching September 2016 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Medicare Part B: Implications for Non-Medical

More information

Drug Money: the illicit proceeds of opiates trafficked on the Balkan route. Executive summary

Drug Money: the illicit proceeds of opiates trafficked on the Balkan route. Executive summary Drug Money: the illicit proceeds of opiates trafficked on the Balkan route Executive summary 2015 Executive summary The cultivation, production and trafficking of illicit opiates accounted for almost

More information

Research & Policy Brief

Research & Policy Brief USM Muskie School of Public Service Maine DHHS Office of Elder Services Research & Policy Brief Caring for People with Alzheimer s Disease or Dementia in Maine A Matter of Public Health Alzheimer s disease

More information

ASSOCIATION ALZHEIMER MAURITIUS WIN EVENT 26 TH SEPTEMBER 2013 DEMENTIA A JOURNEY OF CARING DR AMEENAH SOREFAN

ASSOCIATION ALZHEIMER MAURITIUS WIN EVENT 26 TH SEPTEMBER 2013 DEMENTIA A JOURNEY OF CARING DR AMEENAH SOREFAN ASSOCIATION ALZHEIMER MAURITIUS WIN EVENT 26 TH SEPTEMBER 2013 DEMENTIA A JOURNEY OF CARING DR AMEENAH SOREFAN ALZHEIMER MONTH 21 September International Day for Alzheimer s Disease Launch of World Report

More information

Spain Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen, Denmark, October 2018

Spain Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen, Denmark, October 2018 Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen,, October 2018 LEO Innovation Lab in cooperation with The Happiness Research Institute, 2018. All rights reserved. Any part of

More information

State of provision of Hearing Aids in Europe

State of provision of Hearing Aids in Europe Creating a barrier-free Europe for all hard of hearing citizens State of provision of Hearing Aids in Europe 2018 Report 1 Executive Summary Dear Reader, We are pleased to share the report examining affordability

More information

TOBACCO CONTROL ECONOMICS TOBACCO FREE INITIATIVE PREVENTION OF NONCOMMUNICABLE DISEASES

TOBACCO CONTROL ECONOMICS TOBACCO FREE INITIATIVE PREVENTION OF NONCOMMUNICABLE DISEASES Page 1 1. Smoking prevalence The rate of smoking tends to increase with development reflecting higher prevalence of cigarette use among women as incomes increase. The rate of smoking is relatively high

More information

Hearing Loss: The Statistics

Hearing Loss: The Statistics : The Statistics 2015 Global Statistics It is hard to know precise numbers of how many people experience hearing loss across the EU, Europe, and indeed the world. There are many sources of information

More information

Mental health planners and policymakers routinely rely on utilization

Mental health planners and policymakers routinely rely on utilization DataWatch Measuring Outpatient Mental Health Care In The United States by Mark Olfson and Harold Alan Pincus Abstract: A standard definition of outpatient mental health care does not now exist. Data from

More information

Alcohol in Europe and Brief Intervention. Dr Lars Møller Programme Manager World Health Organization Regional Office for Europe

Alcohol in Europe and Brief Intervention. Dr Lars Møller Programme Manager World Health Organization Regional Office for Europe Alcohol in Europe and Brief Intervention Dr Lars Møller Programme Manager World Health Organization Regional Office for Europe Global risk factors ranked by attributable burden of disease 2010 (GBD, Lancet,

More information

Per Capita Health Care Spending on Diabetes:

Per Capita Health Care Spending on Diabetes: Issue Brief #10 May 2015 Per Capita Health Care Spending on Diabetes: 2009-2013 Diabetes is a costly chronic condition in the United States, medical costs and productivity loss attributable to diabetes

More information

Population Characteristics

Population Characteristics The St. Vital Community Area (CA) is one of 12 community areas (CAs) in the Winnipeg Health Region (WHR). A population health profile has been generated for the St. Vital CA in order to identify its key

More information

The Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert

The Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert Albania. Algeria. Armenia. Austria. Belarus. Belgium. Bosnia & Herzegovina. Bulgaria. Croatia. Cyprus. Czech Republic Denmark. Egypt. Estonia. Finland. Former Yugoslav Republic of Macedonia. France. Georgia.

More information

Socio-economic Consequences of Pain-Intensive Diseases in Denmark

Socio-economic Consequences of Pain-Intensive Diseases in Denmark Summary of publication from the Danish Institute for Health Services Research: Socio-economic Consequences of Pain-Intensive Diseases in Denmark Jan Christensen Lone Bilde Anders Gustavsson The Danish

More information

THE POTENTIAL BENEFIT OF TREATING ALZHEIMER S DISEASE BEFORE THE ONSET DEMENTIA EARLY INTERVENTION: BRIDGING THE EARLY DIAGNOSIS AND TREATMENT GAP

THE POTENTIAL BENEFIT OF TREATING ALZHEIMER S DISEASE BEFORE THE ONSET DEMENTIA EARLY INTERVENTION: BRIDGING THE EARLY DIAGNOSIS AND TREATMENT GAP EARLY INTERVENTION: BRIDGING THE EARLY DIAGNOSIS AND TREATMENT GAP V T OF THE POTENTIAL BENEFIT OF TREATING ALZHEIMER S DISEASE BEFORE THE ONSET DEMENTIA ebc research project - the Value Of treatment For

More information

United Kingdom Editors:

United Kingdom Editors: Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen,, October 2018 LEO Innovation Lab in cooperation with The Happiness Research Institute, 2018. All rights reserved. Any part of

More information

Economic Evaluation. Defining the Scope of a Costeffectiveness

Economic Evaluation. Defining the Scope of a Costeffectiveness Economic Evaluation Defining the Scope of a Costeffectiveness Analysis II This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes

More information

June 2015 MRC2.CORP.D.00030

June 2015 MRC2.CORP.D.00030 This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka America Pharmaceutical, Inc. June 2015 MRC2.CORP.D.00030 advice or professional

More information

had non-continuous enrolment in Medicare Part A or Part B during the year following initial admission;

had non-continuous enrolment in Medicare Part A or Part B during the year following initial admission; Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries Weiss J P, Saynina O, McDonald K M, McClellan M

More information

Partners in Care: A Model of Social Work in Primary Care

Partners in Care: A Model of Social Work in Primary Care Partners in Care: A Model of Social Work in Primary Care Common problems in the elderly, such as reduced cognitive functioning, depression, medication safety, sleep abnormalities, and falls have been shown

More information

The Economic Burden of Hypercholesterolaemia

The Economic Burden of Hypercholesterolaemia The Economic Burden of Hypercholesterolaemia November 2018 TABLE OF CONTENTS Acronyms 3 Executive Summary 4 Introduction 5 Approach 5 Structure of the report 5 Economic burden of hypercholesterolaemia

More information

MENTAL HEALTH DISORDERS: THE ECONOMIC CASE FOR ACTION Mark Pearson Head of Department, OECD Health Division

MENTAL HEALTH DISORDERS: THE ECONOMIC CASE FOR ACTION Mark Pearson Head of Department, OECD Health Division MENTAL HEALTH DISORDERS: THE ECONOMIC CASE FOR ACTION Mark Pearson Head of Department, OECD Health Division The costs of poor mental health Estimates of Direct and Indirect Costs of Mental Illness 1 All

More information

Identifying Adult Mental Disorders with Existing Data Sources

Identifying Adult Mental Disorders with Existing Data Sources Identifying Adult Mental Disorders with Existing Data Sources Mark Olfson, M.D., M.P.H. New York State Psychiatric Institute Columbia University New York, New York Everything that can be counted does not

More information

DIGNITY IN DEMENTIA. G7 dementia legacy event Japan 6 th November 2014

DIGNITY IN DEMENTIA. G7 dementia legacy event Japan 6 th November 2014 G7 dementia legacy event Japan 6 th November 2014 DIGNITY IN DEMENTIA How better policy can improve the lives of people with dementia Mark Pearson Deputy Director Directorate for Employment, Labour and

More information

Identifying best practice in actions on tobacco smoking to reduce health inequalities

Identifying best practice in actions on tobacco smoking to reduce health inequalities Identifying best practice in actions on tobacco smoking to reduce health inequalities An Matrix Knowledge Report to the Consumers, Health and Food Executive Agency, funded by the Health Programme of the

More information

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Publishing Pty Ltd593274279Original ArticleDementia and mild AlzheimersJ. Shimabukuro et al. Psychiatry and

More information

ARE STROKE UNITS COST EFFECTIVE? EVIDENCE FROM A NEW ZEALAND STROKE INCIDENCE AND POPULATION-BASED STUDY

ARE STROKE UNITS COST EFFECTIVE? EVIDENCE FROM A NEW ZEALAND STROKE INCIDENCE AND POPULATION-BASED STUDY ARE STROKE UNITS COST EFFECTIVE? EVIDENCE FROM A NEW ZEALAND STROKE INCIDENCE AND POPULATION-BASED STUDY Braden Te Ao, Ph.D. Centre for Health Services Research & Policy, University of Auckland, National

More information

Denmark Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen, Denmark, October 2018

Denmark Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen, Denmark, October 2018 Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen,, October 2018 LEO Innovation Lab in cooperation with The Happiness Research Institute, 2018. All rights reserved. Any part of

More information

GERIATRIC TEACHING AND TRAINING IN EUROPE: Where are we? (part I)

GERIATRIC TEACHING AND TRAINING IN EUROPE: Where are we? (part I) GERIATRIC TEACHING AND TRAINING IN EUROPE: Where are we? (part I) Pr. Olivier Beauchet, MD, PhD Department of Neuroscience Geriatrics Division and Memory Clinic Angers University Hospital and School of

More information

Unmanaged Behavioral Health Puts Your Company At Risk. Presented by: Dr. Sam Mayhugh Integrated Behavioral Health

Unmanaged Behavioral Health Puts Your Company At Risk. Presented by: Dr. Sam Mayhugh Integrated Behavioral Health Unmanaged Behavioral Health Puts Your Company At Risk Presented by: Dr. Sam Mayhugh Integrated Behavioral Health Behavioral Health Management Webinar Overview History of BH management Prevalence of behavioral

More information

The Long-term Prognosis of Delirium

The Long-term Prognosis of Delirium The Long-term Prognosis of Jane McCusker, MD, DrPH, Professor, Epidemiology and Biostatistics, McGill University; Head, Clinical Epidemiology and Community Studies, St. Mary s Hospital, Montreal, QC. Nine

More information

Source of effectiveness data The effectiveness evidence was derived from a review of published studies.

Source of effectiveness data The effectiveness evidence was derived from a review of published studies. Cost and cost effectiveness of venous and pressure ulcer protocols of care Kerstein M D, Gemmen E, van Rijswijk L, Lyder C H, Phillips T, Xakellis G, Golden K, Harrington C Record Status This is a critical

More information

Note on the harmonisation of SILC and EHIS questions on health

Note on the harmonisation of SILC and EHIS questions on health EUROPEAN COMMISSION EUROSTAT Directorate F: Social statistics and Information Society Unit F-5: Health and food safety statistics 23/01/2008 Note on the harmonisation of SILC and EHIS questions on health

More information

Analysis of Immunization Financing Indicators of the WHO-UNICEF Joint Reporting Form (JRF),

Analysis of Immunization Financing Indicators of the WHO-UNICEF Joint Reporting Form (JRF), Analysis of Immunization Financing Indicators of the WHO-UNICEF Joint Reporting Form (JRF), 2006-2012 Department of Immunization Vaccines and Biologicals, World Health Organization June 2014 1 Table of

More information

Annex 1: MINDMAP research teams

Annex 1: MINDMAP research teams Annex 1: MINDMAP research teams The Department of Public Health from the Erasmus MC in Rotterdam is a leading centre of public health research both within the Netherlands, and internationally and it is

More information

Work package 6, task 2: Review existing care (pathway) approaches for multi-morbidity patients

Work package 6, task 2: Review existing care (pathway) approaches for multi-morbidity patients Work package 6, task 2: Review existing care (pathway) approaches for multi-morbidity patients Mieke Rijken Petra Hopman Janneke Noordman Franςois Schellevis Two activities:.. provide an overview of integrated

More information

Project Meeting Prague

Project Meeting Prague Project Meeting Prague IO1 Assessment 9.11.217 CHRISTINA PADBERG ON BEHALF OF FRANKFURT UAS Current Status Assessment matrix was fully evaluated Experts have been interviewed, Interviews were fully evaluated

More information

The Weston Group, Inc. & Paxxon Healthcare Services, LLC Story

The Weston Group, Inc. & Paxxon Healthcare Services, LLC Story The Weston Group, Inc. & Paxxon Healthcare Services, LLC Story The Weston Group Inc. has been providing rehabilitation services specifically for the geriatric population since the 1980s. Mr. Randall Weston,

More information

Diabetes mellitus is a disorder caused by insufficient or non

Diabetes mellitus is a disorder caused by insufficient or non The Economic Burden of Diabetes Mellitus in the WHO African Region Introduction Diabetes mellitus is a disorder caused by insufficient or non production of the hormone insulin by the pancreas. There are

More information

COMMISSION OF THE EUROPEAN COMMUNITIES

COMMISSION OF THE EUROPEAN COMMUNITIES COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 22.12.2008 COM(2008) 882 final REPORT FROM THE COMMISSION TO THE COUNCIL, THE EUROPEAN PARLIAMENT, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE

More information

Lack of documentation on overweight & obese status in patients admitted to the coronary care unit: Results from the CCU study

Lack of documentation on overweight & obese status in patients admitted to the coronary care unit: Results from the CCU study Lack of documentation on overweight & obese status in patients admitted to the coronary care unit: Results from the CCU study Meriam F. Caboral,, RN, MSN, NP-C Clinical Coordinator Heart Failure Components

More information

COU CIL OF THE EUROPEA U IO. Brussels, 27 July /09 ADD 2 SA 202 SOC 459 RECH 237 COVER OTE

COU CIL OF THE EUROPEA U IO. Brussels, 27 July /09 ADD 2 SA 202 SOC 459 RECH 237 COVER OTE COU CIL OF THE EUROPEA U IO Brussels, 27 July 2009 12392/09 ADD 2 COVER OTE from: SA 202 SOC 459 RECH 237 Secretary-General of the European Commission, signed by Mr Jordi AYET PUIGARNAU, Director date

More information

THE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME

THE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME PERNECZKY 15/06/06 14:35 Page 1 THE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME R. PERNECZKY, A. KURZ Department of Psychiatry and Psychotherapy, Technical University of Munich, Germany. Correspondence

More information

COUNTRY REPORT OF VIET NAM AT THE 12 TH ASEAN & JAPAN HIGH LEVEL OFFICIALS MEETING ON CARING SOCIETIES

COUNTRY REPORT OF VIET NAM AT THE 12 TH ASEAN & JAPAN HIGH LEVEL OFFICIALS MEETING ON CARING SOCIETIES COUNTRY REPORT OF VIET NAM AT THE 12 TH ASEAN & JAPAN HIGH LEVEL OFFICIALS MEETING ON CARING SOCIETIES 21-23 OCTOBER 2014 I. AGEING POPULATION IN VIETNAM 1. Vietnam is one of 10 countries with the world

More information

Economic burden of non-malignant blood disorders across Europe: a population-based cost study

Economic burden of non-malignant blood disorders across Europe: a population-based cost study Articles Economic burden of non-malignant blood disorders across Europe: a population-based cost study Ramon Luengo-Fernandez, Richeal Burns, Jose Leal Summary Background Blood disorders comprise a wide

More information

Study population Patients in the UK, with moderate and severe depression, and within the age range 18 to 93 years.

Study population Patients in the UK, with moderate and severe depression, and within the age range 18 to 93 years. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK Borghi J, Guest J F Record Status This is a critical abstract

More information

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Dementia: the management of dementia, including the use of antipsychotic medication in older people

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Dementia: the management of dementia, including the use of antipsychotic medication in older people NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Dementia: the management of dementia, including the use of antipsychotic medication in older people 1.1 Short title Dementia 2 Background

More information

United States Editors:

United States Editors: Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen,, October 2018 LEO Innovation Lab in cooperation with The Happiness Research Institute, 2018. All rights reserved. Any part of

More information

Alzheimer s Disease Facts

Alzheimer s Disease Facts Alzheimer s Disease Facts and Figures 2008: A Report from the Alzheimer s Association PART 4 Alzheimer s Disease Facts and Figures 2008 is a comprehensive statistical abstract of US data on Alzheimer s

More information

Monetary Costs of Dementia in the United States

Monetary Costs of Dementia in the United States T h e n e w e ngl a nd j o u r na l o f m e dic i n e special article Monetary Costs of Dementia in the United States Michael D. Hurd, Ph.D., Paco Martorell, Ph.D., Adeline Delavande, Ph.D., Kathleen J.

More information

NBER WORKING PAPER SERIES ALCOHOL CONSUMPTION AND TAX DIFFERENTIALS BETWEEN BEER, WINE AND SPIRITS. Working Paper No. 3200

NBER WORKING PAPER SERIES ALCOHOL CONSUMPTION AND TAX DIFFERENTIALS BETWEEN BEER, WINE AND SPIRITS. Working Paper No. 3200 NBER WORKING PAPER SERIES ALCOHOL CONSUMPTION AND TAX DIFFERENTIALS BETWEEN BEER, WINE AND SPIRITS Henry Saffer Working Paper No. 3200 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge,

More information

NEUROPSYCHOMETRIC TESTS

NEUROPSYCHOMETRIC TESTS NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract

More information

Abert Borchette Conference Centre European Commission- Room 1C Bruxelles 5th April 2017

Abert Borchette Conference Centre European Commission- Room 1C Bruxelles 5th April 2017 Abert Borchette Conference Centre European Commission- Room 1C Bruxelles 5th April 2017 Sunfrail Tool for the identification of Frailty and Multimorbidity Marcello Maggio UOC Clinica Geriatrica Dipartimento

More information

Palliative nursing care of children and young people across Europe

Palliative nursing care of children and young people across Europe Palliative nursing care of children and young people across Europe Results of a postal survey in August 2016 Updated in April 2017 (presented at the 29th PNAE-meeting in Naples/Italy on 28th April 2017)

More information